Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to solve genetically complex problems. The company is headquartered in Menlo Park, California.
| Revenue (TTM) | $161.39M |
| Gross Profit (TTM) | $44.59M |
| EBITDA | $-153.03M |
| Operating Margin | -90.50% |
| Return on Equity | -929.00% |
| Return on Assets | -43.50% |
| Revenue/Share (TTM) | $0.53 |
| Book Value | $-0.20 |
| Price-to-Book | 170.66 |
| Price-to-Sales (TTM) | 4.34 |
| EV/Revenue | 7.66 |
| EV/EBITDA | 140.79 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 5.50% |
| Shares Outstanding | $310.83M |
| Float | $304.58M |
| % Insiders | 8.86% |
| % Institutions | 57.24% |
Volatility is currently contracting
Pacific Biosciences reported mixed Q3 results, with revenues beating reduced estimates but gross margins falling. Despite continually declining street revenue estimates, management was disappointed with guidance as it trimmed its 2026 sales forecast. The company continues to burn large amounts of cash, weakening the balance sheet considerably over time.
Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026.
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PACB and any ticker you trade — then tracks every position and per-strategy win rate.
